top of page

PROGRAMME   EHMSG Workshop

Friday, September 13, 2024

 

08.25 – 08.30 hrs | Welcome by EHMSG President José Machado

08.30 – 10.30 hrs | Session 1:  Hot topics in H.pylori and gut microbiota

08.30 – 08.50 hrs                

1.1. The person-to-person transmission landscape of the gut and oral microbiomes

Vitor Heidrich, Italy

08.50 – 09.10 hrs                

1.2. New drugs targeting H. pylori envelopes

Ivo Boneca, France

09.10 – 09.30 hrs                

1.3. Evolving concepts in H. pylori management

Shailja Shah, United States

09.30 – 09.50 hrs                

1.4. Vaccination Protects Against Gastric Cancer

Thomas Boren, Umea, Sweden

09.50 – 10.10 hrs                

1.5. Evolution of the prevalence and incidence of Helicobacter pylori infection

Jyh-Ming Liou, Taiwan

10.10 – 10.30 hrs                

1.6. GWAS on H. pylori seroprevalence

Constanza Camargo, Rockville, MD, United States

10.30 – 11.00 hrs | Coffee Break

 

11.00 – 12.45 hrs | Session 2: News on gastritis (Parallel Session)

11.00 – 11.20 hrs                

02.01 The RE.GA.IN consensus project

Massimo Rugge, Italy

11.20 – 11.40 hrs                

02.02 Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori-negative patients

Ludovica Bricca, Italy

11.40 – 12.00 hrs                

02.03 Trends in the prevalence of atrophic gastritis and Helicobacter pylori in Far East

Yoshio Yamaoka, Japan

12.00 – 12.15 hrs                

02.04 Helicobacter pylori Seroprevalence In Histologically H. pylori-Negative Autoimmune Atrophic Gastritis Patients

Edith Lahner, Rome, Italy

12.15 – 12.30 hrs                

02.05. Interleukin‐27 Is Highly Expressed In The Serum And Gastric Mucosa Of Children With H. pylori‐Associated Gastroduodenal Diseases

Dulciene Queiroz, Belo Horizonte, Brasil

12.30 – 12.45 hrs                

02.06 Autoimmune Gastritis In Pediatric Age And Its Relationship With H. pylori Infection

Inês Aires Martins, Porto, Portugal

 

11.00 – 12.45 hrs |Session 3: Microbiome mechanisms of action (Parallel Session)

11.00 – 11.20 hrs                

03.01 Protein fermentation products and health outcomes

Silvio Waschina, Kiel, Germany

11.20 – 11.40 hrs                

03.02 Mechanisms of microbiome engraftment

Gianluca Ianiro, Italy

11.40 – 12.00 hrs                

03.03 Mycobiome in IBD

Petra Bacher, Germany

12.00 – 12.15 hrs                

03.04 Microbiome Composition In Patients With Upper Gastrointestinal Cancer And Small Intestinal Bacterial Overgrowth (SIBO)

Marino Venerito, Magdeburg, Germany

12.15 – 12.30 hrs                

03.05. The Impacts Of The Crosstalk Between Bacterial Vaginosis Associated Bacteria And Trichomonas Vaginalis On The Pathogenesis And Host Immune Responses

Shu-Fang Chiu, Taipei, Taiwan

12.30 – 12.45 hrs                

03.06 Mycobiome Dysbiosis In Liver Cirrhosis Patients

Darja Nikitina, Kaunas, Lithuania

 

12.45 – 14.00 hrs | Lunch Break & Poster Viewing

 

14.00 – 15.00 hrs | Session 4: Industry-Sponsored Satellite Symposium

Click HERE for details

15.00 – 16.45 hrs | Session 5: Helicobacter pylori: Genetics and Beyond (Parallel Session)

15.00 – 15.20 hrs                

05.01 Differences in H. pylori population structures worldwide

Kaisa Thorell, Sweden

15.20 – 15.40 hrs                

05.02  H. pylori evolution depends on niche specific physiological conditions

Sebastian Suerbaum, Germany

15.40 – 16.00 hrs                

05.03 Impact of H. pylori on mucosal immunity and colorectal cancer

Markus Gerhard, Germany

 

16.00 – 16.15 hrs                

05.04 Helicobacter pylori Infection Leads To Systemic Metabolic Reprogramming Through The Il-6/JAK/STAT3 Pathway

Bingting Yu, Rotterdam, Netherlands

16.15 – 16.30 hrs                

05.05 The H. pylori Autotransporter ImaA Associates With Extracellular Vesicles To Modulate Host Inflammatory Responses In Gastric Epithelial Cells

Angus Cramond, Clayton, Australia

16.30 – 16.45 hrs                

05.06 The Prophages Of The Helicobacter Genus

Filipa Vale, Lisbon, Portugal

 

15.00 – 16.45 hrs | Session 6: Oncobiome (Parallel Session)

                                            

15.00 – 15.20 hrs                

06.01 Microbiome mediated inflammation in colon cancer

Mathias Chamaillard, Lille, France

15.20 – 15.40 hrs                

06.02 Predicting CRC survival post-surgical resection using tumour microbial profiling

James Alexander, United Kingdom

15.40 – 16.00 hrs                

06.03 Microbiota-modulated immune checkpoint

Carolina Alves Costa Silva, France

16.00 – 16.15 hrs                

06.04 Longitudinal Definition Of The Gastric Microbiome From A High-Gastric-Cancer-Risk Cohort From Colombia, South America

Anthony Mannion, United States

16.15 – 16.30 hrs                

06.05 Characterization Of The Intratumoral Microbiota In Gastric Cancer Patients

Marine Jauvain, Bordeaux, France

16.30 – 16.45 hrs                

06.06 Microbiome-Derived Metabolites As Novel Biomarkers Of Gastric Cancer

Rui Ferreira, Porto, Portugal

 

16.45 – 17.15 hrs | Coffee Break

 

17.15 – 19.00 hrs | Session 7: Gastric Carcinogenesis (Parallel Session)

17.15 – 17.35 hrs                

07.01 Microbiome and gastric cancer

Ceu Figueiredo, Portugal

 

17.35 – 17.55 hrs                

07.02 Gastric Intestinal Metaplasia an Innocent Bystander in Gastric Cancer?

Ken Sugano, Japan

17.55 – 18.15 hrs                

07.03 Natural History of Sporadic and Hereditary Diffuse Gastric Carcinoma: From Onset to Progression

Fatima Carneiro, Portugal

 

18.15 – 18.30 hrs                

07.04 Unveiling Plasma Protein Signatures For Gastric Preneoplasia And Cancer Lesion Detection

Eliette Touati, Paris, France

18.30 – 18.45 hrs                

07.05 Gastric Cancer Invasion: Physical And Biochemical Nuclear Readouts Elicited By E-Cadherin Loss

Joana Figueiredo, Porto, Portugal

18.45 – 19.00 hrs                

07.06 The Autophagy Protein IRGM Is A Key Player In Gastric Carcinogenesis

Elsa Kalluzhathil, Kensington, Australia

 

17.15 – 19.00 hrs | Session 8: FMT session (Parallel Session)

17.15 – 17.35 hrs                

08.01 Safety in FMT

Josbert Keller, Netherlands

17.35 – 17.55 hrs                

08.02 Regulation of FMT and donor screening

Christian Hvas, Denmark

                                            

17.55 – 18.15 hrs                

08.03 How to improve FMT success

Alexander Link, Germany

 

15.15 – 18.30 hrs                

08.04 Effectiveness Of Fecal Microbiota Transplant In Metabolic Syndrome:  A Randomized Double-Blinded Placebo-Controlled Trial

Ratha-korn Vilaichone, Pathumthani,Thailand

18.30 – 18.45 hrs                

08.05 Fecal Microbiota Transplantation (FMT) Versus Placebo In Patients Receiving Pembrolizumab Plus Axitinib For Advanced Renal Cell Carcinoma. A Double-Blind Randomized Controlled Trial (TACITO Trial)

Gianluca Ianiro, Rome, Italy

18.45 – 19.00 hrs                

08.06 Efficacy And Safety Of Fecal Microbiota Transplantation In Patients With Irritable Bowel Syndrome: A Preliminary Report

Ho-Kyoung Lee, Seoul, Republic of Korea

 

20.00 hrs                             

EHMSG Conference Dinner


 

Saturday, September 14, 2024

 

08.30 – 09.15 hrs | Session 9: Memorial Talks

08.30 – 08.45 hrs                 

09.01 In Memoriam Ashley Price

Anthony Axon, United Kingdom

                                            

08.45 – 09.00 hrs                

09.02 In Memoriam Pentti Sipponen

Ari Ristimäki, Finland

 

09.00 – 09.15 hrs                

09.03 In Memoriam Adrian Lee

Jim Fox, United States

09.15 – 11.00 hrs | Session 10: H. pylori management (Parallel Session)

09.15 – 09.35 hrs                

10.01 Current role of tailored therapy in treating H. pylori infection

Theodore Rokkas, Greece

09.35 – 09.55 hrs                

10.02 The rebirth of Bismuth in H. pylori eradication

Rocco Maurizio Zagari, Italy

09.55 – 10.15 hrs                

10.03 Latin American Registry on the Management of H. pylori Infection (Hp-LATAMReg)

Arnoldo Riquelme, Chile 

10.15 – 10.30 hrs                

10.04 Effectiveness And Safety Of First-Line Empirical Non-Bismuth Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapies In Spain: Analysis Of 12,000 Patients From The European Registry On Helicobacter pylori Management (Hp-Eureg)

Olga Nyssen, Madrid, Spain

10.30 – 10.45 hrs                

10.05 A Novel Multi-Epitope-Based Vaccine Against H. pylori; Evaluation Of The Protective Effect
Behnam Kalali, Munich, Germany

10.45 – 11.00 hrs                

10.06 7-Day Therapy Vs. 14-Day Therapy In Empirical And Tailored Therapy: A Placebo-Controlled Randomized Nationwide Trial In Korea

Byung-Wook Kim, Incheon, Republic of Korea

09.15 – 11.00 hrs | Session 11: Probiotics (Parallel Session)

09.15 – 09.35 hrs                

11.01 Use of probiotics in chronic liver diseases

Luca Miele, Italy

09.35 – 09.55 hrs                

11.02 Inflammatory bowel diseases: when can probiotics be helpful?

Loris Lopetuso, Italy

09.55 – 10.15 hrs                

11.03 Dietary Sulforaphane Increases Butyrate-Producing Intestinal Microbiota And Decreases Fecal Calprotectin Level In Patients With Ulcerative Colitis

Akinori Yanaka, Tsukuba, Japan

10.15 – 10.30 hrs                

11.04 The Beneficial Effect Of A Probiotic Intervention On Quality Of Sleep - A Randomized, Double-Blinded, Placebo-Controlled Study

Angela Horvath, Graz, Austria

10.30 – 10.45 hrs                

11.05 Bifidobacterium Modulates The Immune Response In A Microsatellite Instability Colorectal Cancer Mouse Model

Patricia Vieira, Porto, Portugal

10.45 – 11.00 hrs                

11.06 Bacterial Genotoxins Trigger Invadosome Formation Associated To Matrix Degradation

Lamia Azzi-Martin, Bordeaux, France

11.00 – 11.30 hrs | Coffee Break

 

11.30 – 13.30 hrs | Session 12: Debates – Gastric cancer screening

11.30 – 11.50 hrs                

12.01 Optimal strategies for gastric cancer screening – targeted vs. population based

Iris Lansdorp Vogelaar, Netherlands

11.50 – 12.10 hrs                

12.02 What is the optimal age for screening?

Jan Bornschein, United Kingdom

12.10 – 12.30 hrs                

12.03 Is there a role for endoscopy and AI in gastric cancer screening

Mario Dinis Ribeiro, Portugal

12.30 – 12.50 hrs                

12.04 Gastric cancer screening experience in Japan

Hidekazu Suzuki , Japan

12.50 – 13.10 hrs                

12.05 Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A                     Nationwide Cohort Study

Hae Won Yoo, Korea

13.10 – 13.30 hrs                

12.06 Helicobacter pylori treatment and risk of gastric cancer in large intervention trials in China

Wen Qing Li, China

13.30 – 15.00 hrs | Lunch Break & Poster Viewing

 

15.00 – 17.00 hrs |Session 13: Updates in Helicobacter & Microbiota

15.00 – 15.20 hrs                

13.01 Million Microbiome from Humans Project

Lars Engstrand, Sweden

15.20 – 15.40 hrs                

13.02 tba

tba

15.40 – 16.00 hrs                

13.03 Effect of faecal microbiota transplantation on multidrug-resistant bacteria and the resistome

Elizabeth Terveer, The Netherlands

16.00 – 16.20 hrs                

13.04 The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection

Cristina Martins, Portugal

16.20 – 16.40 hrs                

13.05 Novel principles for cure of H. pylori infection

Peter Malfertheiner, Germany

16.40 – 17.00 hrs                

13.06 Histamine Signaling Is Essential for Tissue Macrophage Differentiation and Suppression of Bacterial Overgrowth in the Stomach Cell

Ki Taek Nam, Korea

      

17.00 – 18.00 hrs | Session 14: Closing Session

17.00 – 17.20 hrs                

14.01 Awarding of the Marshall and Warren Medal 2024 to Fatima Carneiro, Porto, Portugal

17.20 – 17.35 hrs

14.02 Awarding of the EHMSG Oral and Poster Awards

17.35 – 17.50 hrs

14.03 Presentation of the EHMSG Journal

Francesco Franceschi, Italy

17.50 – 18.00 hrs                

14.04 Presentation of the next meeting in Rome, Italy

Gianluca Ianiro, Italy

Closing Remarks

bottom of page